Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.
Advocacy Opportunities Abound at ACR Convergence
At ACR Convergence 2025, the ACR advocacy team will be hosting a slate of programming to help you understand the power of advocacy and prepare you to add your voice in support of the rheumatology community.
ACR Leads Sign-on Letter to Cigna Opposing Downcoding of E/M Claims
The ACR recently led a rheumatology community letter to Cigna opposing the payer’s decision to downcode level 4 and 5 evaluation and management claims.
ACR Delegates Prepare for Fall Season Advocacy with the AMA
The ACR’s delegation to the American Medical Association’s House of Delegates is gearing up for the HOD Interim Meeting, slated for Nov. 14–18. Several members share their views on the value of this advocacy work and top issues this fall.
ACR Advocates for Fair Reimbursement & Telehealth Flexibility in MPFS 2026 Proposed Rule
In comments to the CMS, the ACR advocated for telehealth flexibilities and fair reimbursement and pushed back on proposed efficiency adjustments and changes likely to increase administrative burden on practices.
Include Advocacy in Your ACR Convergence 2025 Plans
Check out this quick guide to advocacy events and programming that will help you leave Chicago informed and ready to be an advocate for the rheumatology community back home.
President’s Corner: The ACR Is on Your Side
Encouraging lawmakers to pass legislation and promote policies that positively affect rheumatologists, rheumatology care teams and those living with rheumatic disease is one of the most impactful ways the ACR advances its mission. The role of advocacy has never been more critical than in recent months, when we have seen an unprecedented number of executive…
ACR Urges Strong AI Safeguards in State Model Legislation
In comments to the National Association of Insurance Commissioners, the ACR outlined several recommendations for a proposed state model law addressing the use of artificial intelligence in the insurance industry.
Aetna Implements Specialty Pharmacy Requirements
On July 1, Aetna launched its new Combined Benefit Management Drug List, effectively moving romosozumab-aqqg (Evenity) and infliximab (Remicade) to pharmacy-only coverage for most fully insured commercial plans. The ACR has contacted Aetna leaders to raise concerns about patient access to these therapies.
ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting
An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.
- 1
- 2
- 3
- …
- 11
- Next Page »